GlassScriptPhysician profile
Daron G Street
NPI 1083656912
$54,523.69
in general payments reported to CMS, 2019-2025
53 companies · $8,233 in 2025
The $8,233 reported for 2025 was more than what 89% of Gynecologic Oncology providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,278 · 2020: $6,046 · 2021: $21K · 2022: $3,104 · 2023: $6,484 · 2024: $3,920 · 2025: $8,233.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,633 · Consulting Fee: $6,499 · Education: $4,000 · Travel and Lodging: $505.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,632.97 |
| Consulting Fee | $6,498.67 |
| Education | $4,000.00 |
| Travel and Lodging | $504.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coherus Oncology, INC. | $22,779.07 | 2020-2025 | Loqtorzi |
| Glaxosmithkline, LLC. | $5,422.17 | 2021-2025 | Jemperli, Zejula, Ojjaara |
| Intuitive Surgical, INC. | $4,932.42 | 2019-2025 | Da Vinci Surgical System |
| Tesaro, INC. | $4,338.71 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $2,469.00 | 2019-2025 | |
| Heron Therapeutics, INC. | $1,656.41 | 2019-2024 | Cinvanti |
| Asd Specialty Healthcare, LLC | $1,505.77 | 2019-2025 | |
| Myriad Genetic Laboratories, INC. | $1,462.05 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $1,192.52 | 2023 | Libtayo |
| Aveo Pharmaceuticals, INC. | $1,118.96 | 2023 | Fotivda |
| Eagle Pharmaceuticals, INC. | $722.64 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $672.67 | 2023-2025 | Keytruda |
| Cardinal Health 108 LLC | $650.96 | 2023-2025 | |
| Spectrum Pharmaceuticals INC. | $566.85 | 2023 | Rolvedon |
| Amgen INC. | $530.82 | 2022-2025 | Blincyto, Imdelltra (Amg757), Lumakras |
Show all 52 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daron Street listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.